Eli Lilly delivered a Q1 2026 trifectaearnings beat, raised full-year guidance, and early-April FDA approval of Foundayo, the first oral GLP-1 with no food or water restrictionswidening its lead over Novo Nordisk just as the race for a convenient weight-loss pill heats up
It has both flavored and unflavored options and is third-party tested for quality and purity
Material and methods Animals 60 male C57BL/6J mouse (68 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd
Among those who have used GLP-1 drugs, about half report they have experienced nausea and about one-third experienced diarrheathe two most-common side effects associated with the medications
Its designed to stimulate the pituitary gland to increase the production of growth hormone (GH) , which in turn raises levels of IGF-1 a key hormone involved in metabolism, fat burning, and muscle maintenance